The dose-dependent down-regulation of pro-inflammatory nuclear factor-kappa B (NF-κB), tumor necrosis factor alpha (TNF-α), and IL-6 mRNA levels by the FD extract considerably at P < 0.05 alleviated these bone microstructural and biomarker alterations. In this OP/osteoarthritis (OA) preclinical model, the FD extract showed good anti-osteoporotic characteristics by increasing bone formation and reducing bone resorption via anti-inflammatory pathways. The gene discussed is TNF; the disease is osteoarthritis.